Nalu Medical Closes $65 Million Series E Financing

Nalu Medical has closed $65 million Series E Financing led by new investor Novo Holdings, an investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, to accelerate commercial growth, expand clinical and health-economic evidence, continue product development, and scale operations.

All existing investors participated in the financing, including Gilde Healthcare, MVM Partners, Endeavor Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida and Aperture Venture Partners.

Based in Carlsbad, California, Nalu Medical is focused on the development and commercialization of innovative and minimally invasive solutions for patients suffering from chronic neuropathic pain. The Nalu Neurostimulation System delivers gentle electrical pulses to the nervous system to modulate pain signals before they reach the brain. The Nalu System is designed to address significant unmet needs in the treatment of chronic neuropathic pain and provide a differentiated value proposition for patients and physicians.

To view the source version, please click HERE.